Total Current assets Total assets Total current liabilities Total non-current liabilities Total liabilities Total capital deficiency Balance Balance Total liabilities and capital deficiency Net loss Comprehensive loss for the period Net loss Net loss (in Dollars) Balance (in Shares) Balance (in Shares) Class of Stock [Axis] Equity Components [Axis] Net cash used in operating activities Net cash used in investing activities Net cash provided by financing activities INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF YEAR CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF YEAR Total cash and cash equivalents and restricted cash General [Abstract] Significant Accounting Policies [Abstract] Fair Value Measurements [Abstract] Total assets Total liabilities Fair Value Hierarchy and NAV [Axis] Measurement Frequency [Axis] Beginning balance Ending balance Measurement Input Type [Axis] Statistical Measurement [Axis] Other Current Assets [Abstract] Schedule of Other Current Assets [Abstract] Total Other current assets Other Account Payables [Abstract] Total Deconsolidation of Biomx Ltd [Abstract] Schedule of Deconsolidation [Abstract] Stockholders Equity [Abstract] Class of Warrant or Right [Axis] Number of Options, Outstanding at the beginning of period Number of Options, Outstanding at the end of period Weighted Average Exercise Price, Outstanding at the beginning of period Weighted Average Exercise Price, Outstanding at the end of period Aggregate Intrinsic Value, Outstanding at the beginning of period Aggregate Intrinsic Value, Outstanding at the end of period Derivative Instrument [Axis] Statement of Incomes Location, Balance [Axis] Basic and Diluted Loss Per Share [Abstract] Antidilutive Securities [Axis] Segment Reporting [Abstract] Total Operating expenses Segments [Axis] Geographical [Axis] Subsequent Events [Abstract] Assets Assets: Current Assets Cash and cash equivalents Restricted cash Property and equipment, held for sale Non-current Assets In-process Research and development (“IPR&D”) asset Liabilities and Capital Deficiency Current Liabilities Trade account payables Balance due Biomx Ltd Current portion of lease liabilities Other account payables Non-current Liabilities Warrants Purchase of warrants (in Dollars) Capital deficiency Preferred Stock, $0.0001 par value; Authorized - 1,000,000 shares as of March 31, 2026 and December 31, 2025. Issued and outstanding – 147,512 as of March 31, 2026 and 147,512 shares as of December 31, 2025. Preferred stock, par value (in Dollars per share) Preferred stock, shares authorized (in Shares) Preferred stock, shares authorized Preferred stock, shares issued (in Shares) Preferred stock, shares issued Preferred stock, shares outstanding (in Shares) Common stock, $0.0001 par value (“Common Stock”); Authorized - 750,000,000 shares as of March 31, 2026 and December 31, 2025. Issued and outstanding – 6,543,703 and 1,593,703 as of March 31, 2026 and December 31, 2025, respectively. Common stock, par value (in Dollars per share) Common stock, shares authorized (in Shares) Common stock, shares authorized Common stock, shares issued (in Shares) Common stock, shares outstanding (in Shares) Additional paid-in capital Accumulated deficit Operating expenses: Research and development (“R&D”) expenses, net General and administrative expenses Interest expenses Day one loss upon entering transaction Tax expenses Basic loss per share of Common Stock (in Dollars per share) Basic loss per share of common stock (in Dollars per share) Diluted loss per share of Common Stock (in Dollars per share) Diluted loss per share of common stock (in Dollars per share) Weighted average number of shares used in computing basic loss per share of Common Stock (in Shares) Issuance of Series Y Convertible Preferred Stock Issuance of Series Y Convertible Preferred Stock (in Shares) Series Y convertible preferred stock Conversion of Series Y Convertible Preferred Stock into common stock Conversion of Series Y Convertible Preferred Stock into common stock (in Shares) Converted shares Exercise of warrants into common stock Exercise of warrants into common stock Reclassification of embedded conversion derivative upon conversion of Series Y Convertible Preferred Stock Share based compensation Issuance of Common Stock, Registered Pre- Funded Warrants and Private Pre-Funded Warrants under the February 2025 SPA, net of issuance costs Issuance of Common Stock, Registered Pre- Funded Warrants and Private Pre-Funded Warrants under the February 2025 SPA, net of issuance costs (in Shares) Issuance of Common Stock under Inducement Letter Agreements Issuance of Common Stock under Inducement Letter Agreements (in Shares) CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments required to reconcile net loss for the year to net cash used in operating activities: Depreciation Stock-based compensation Revaluation of contingent consideration Value of warrants issued in connection with private placement Changes in operating assets and liabilities: Trade accounts payable Other accounts payable Net change in operating leases CASH FLOWS FROM INVESTING ACTIVITIES: Proceeds from sale of property and equipment CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of preferred share and warrants under January 2026 private placement, net of issuance costs Aggregate gross proceeds (in Dollars) Issuance of Common Stock under February 2025 SPA Aggregate gross proceeds (in Dollars) Issuance of Common Warrants under February 2025 SPA Issuance of Common Stock under Inducement Letter Agreements Effect of exchange rate changes on cash and cash equivalents RECONCILIATION OF AMOUNTS ON CONSOLIDATED BALANCE SHEETS Restricted cash SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash paid for interest Taxes paid SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES Accrued Preferred dividends on Series Y Convertible Preferred Stock Conversion of warrants into common stock Conversion of Series Y Convertible Preferred Stock into common stock Reclassification of Series Y Convertible Preferred Stock to permanent equity Receivables on account of shares Operating loss Other expenses (income) Net gain from deconsolidation of subsidiary Loss (income) from change in derivatives financial instruments measured at fair value Finance expense, net Net loss before tax Preferred dividends on Series Y Convertible Preferred Stock Preferred dividends on Series Y Convertible Preferred Stock (in Dollars) Finance income, net Loss (income) from change in fair value of liability-classified warrants Loss from sale and disposal of fixed assets, net Gain from deconsolidation of subsidiary Other current assets Decrease in cash as a result of deconsolidation of subsidiary February 2025 SPA issuance costs Series Y Redeemable Convertible Preferred Shares Preferred Shares [Member] Preferred Stock [Member] Series X Redeemable Convertible Common stock Common Stock [Member] Additional paid-in capital Accumulated deficit Receivables on account of shares Redeemable Convertible Preferred Shares GENERAL Significant Accounting Policies FAIR VALUE MEASUREMENTS Schedule of Financial Assets that are Measured at Fair Value on a Recurring Basis by Level Cash equivalents: Money market funds US$ Assets: Cash equivalents: Liabilities: Liabilities: Schedule of Fair Value of the Level 3 Liabilities Liability: Issuance of Common Warrants Repricing of warrants under the Inducement Letter Agreements Exercise of warrants into common stock Change in terms of warrant liability Warrant liability (in Dollars) Change in fair value Schedule of Fair Value of the Liabilities for the Warrants Fair values of liabilities OTHER CURRENT ASSETS Schedule of Other Current Assets Government institutions Prepaid insurance Other prepaid expenses Other OTHER ACCOUNT PAYABLES Schedule of Other Account Payables Employees and related institutions Accrued expenses Government institutions DECONSOLIDATION OF BIOMX LTD Schedule of Deconsolidation Cash and cash equivalents Other current assets Fixed assets